The development of novel treatments that are effective and well-tolerated, and their use in combination with ET as part of a first-line regimen for advanced disease in patients with HR+/HER2− advanced breast cancer, has led to improvements in progression-free survival [39]. This evidence concerns the gene HR and breast carcinoma.